First Light Diagnostics, a Chelmsford, Mass.-based developer of automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, closed an $8.25 million Series A-2 financing.
The financing included new investment partners from Think.Health Ventures, 10x Group, and Beacon Angels, along with new individual investors and continued participation from current shareholders such as LRV Health and Life Science Angels.
The company intends to use the funds to continue development of the MultiPath™ technology to rapidly detect hospital infections and determine their susceptibility to specific antibiotics. This includes preparation and support for product commercialization and launch in early 2020.
Led by David Macdonald, CEO, and Don Straus, Founder and primary inventor of the core scientific technology, First Light Diagnostics is developing and preparing to commercialize, innovative diagnostic products for rapid and sensitive detection of life-threatening infections, and combating the spread of antibiotic resistance.
Based on its proprietary MultiPath™ detection technology, First Light’s tests rapidly detect infections, identify infectious agents, and determine effective targeted antibiotic therapy.